Kabir O Olaniran1,2, Andrew S Allegretti3, Sophia H Zhao3, Maureen M Achebe4, Nwamaka D Eneanya5, Ravi I Thadhani3,6, Sagar U Nigwekar3, Sahir Kalim3. 1. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; kolaniran@mgh.harvard.edu. 2. Division of Nephrology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas. 3. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 4. Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and. 6. Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
BACKGROUND: Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood. METHODS: Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by electrophoresis) and at least 1 year of follow-up and three eGFR values. We used linear mixed models to evaluate the difference in the mean change in eGFR per year. RESULTS: We identified 1251 patients with sickle cell trait, 230 with sickle cell disease, and 8729 reference patients, with a median follow-up of 8 years. After adjustment, eGFR declined significantly faster in patients with sickle cell trait or sickle cell disease compared with reference patients; it also declined significantly faster in patients with sickle cell disease than in patients with sickle cell trait. Male sex, diabetes mellitus, and baseline eGFR ≥90 ml/min per 1.73 m2 were associated with faster eGFR decline for both phenotypes. In sickle cell trait, low hemoglobin S and elevated hemoglobin A were associated with faster eGFR decline, but elevated hemoglobins F and A2 were renoprotective. CONCLUSIONS: Sickle cell trait and disease are associated with faster eGFR decline in black patients, with faster decline in sickle cell disease. Low hemoglobin S was associated with faster eGFR decline in sickle cell trait but may be confounded by concurrent hemoglobinopathies. Prospective and mechanistic studies are needed to develop best practices to attenuate eGFR decline in such patients.
BACKGROUND: Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood. METHODS: Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by electrophoresis) and at least 1 year of follow-up and three eGFR values. We used linear mixed models to evaluate the difference in the mean change in eGFR per year. RESULTS: We identified 1251 patients with sickle cell trait, 230 with sickle cell disease, and 8729 reference patients, with a median follow-up of 8 years. After adjustment, eGFR declined significantly faster in patients with sickle cell trait or sickle cell disease compared with reference patients; it also declined significantly faster in patients with sickle cell disease than in patients with sickle cell trait. Male sex, diabetes mellitus, and baseline eGFR ≥90 ml/min per 1.73 m2 were associated with faster eGFR decline for both phenotypes. In sickle cell trait, low hemoglobin S and elevated hemoglobin A were associated with faster eGFR decline, but elevated hemoglobins F and A2 were renoprotective. CONCLUSIONS: Sickle cell trait and disease are associated with faster eGFR decline in black patients, with faster decline in sickle cell disease. Low hemoglobin S was associated with faster eGFR decline in sickle cell trait but may be confounded by concurrent hemoglobinopathies. Prospective and mechanistic studies are needed to develop best practices to attenuate eGFR decline in such patients.
Authors: Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles Journal: J Am Soc Nephrol Date: 2017-01-31 Impact factor: 10.121
Authors: Marianne E M Yee; Peter A Lane; David R Archer; Clinton H Joiner; James R Eckman; Antonio Guasch Journal: Am J Hematol Date: 2017-07-29 Impact factor: 10.047
Authors: Paula J Griffin; Paola Sebastiani; Heather Edward; Clinton T Baldwin; Mark T Gladwin; Victor R Gordeuk; David H K Chui; Martin H Steinberg Journal: Am J Hematol Date: 2014-08-04 Impact factor: 10.047
Authors: Kabir O Olaniran; Andrew S Allegretti; Sophia H Zhao; Sagar U Nigwekar; Sahir Kalim Journal: Clin J Am Soc Nephrol Date: 2021-03-08 Impact factor: 8.237
Authors: Anthony J Bleyer; Maggie Westemeyer; Jing Xie; Michelle S Bloom; Katya Brossart; Jason J Eckel; Frederick Jones; Miklos Z Molnar; Wayne Kotzker; Prince Anand; Stanislav Kmoch; Yuan Xue; Samuel Strom; Sumit Punj; Zachary P Demko; Hossein Tabriziani; Paul R Billings; Trudy McKanna Journal: Am J Nephrol Date: 2022-03-24 Impact factor: 4.605
Authors: Rachel K Y Hung; Elizabeth Binns-Roemer; John W Booth; Rachel Hilton; Julie Fox; Fiona Burns; Mark Harber; Andrew Ustianowski; Lisa Hamzah; James E Burns; Amanda Clarke; David A Price; Stephen Kegg; Denis Onyango; Beatriz Santana-Suarez; Lucy Campbell; Kate Bramham; Claire C Sharpe; Caroline A Sabin; Cheryl A Winkler; Frank A Post Journal: Kidney Int Rep Date: 2021-12-13
Authors: Nwamaka D Eneanya; L Ebony Boulware; Jennifer Tsai; Marino A Bruce; Chandra L Ford; Christina Harris; Leo S Morales; Michael J Ryan; Peter P Reese; Roland J Thorpe; Michelle Morse; Valencia Walker; Fatiu A Arogundade; Antonio A Lopes; Keith C Norris Journal: Nat Rev Nephrol Date: 2021-11-08 Impact factor: 42.439
Authors: Anthony Batte; Sahit Menon; John Ssenkusu; Sarah Kiguli; Robert Kalyesubula; Joseph Lubega; Edrisa Ibrahim Mutebi; Robert O Opoka; Chandy C John; Michelle C Starr; Andrea L Conroy Journal: BMC Nephrol Date: 2022-03-18 Impact factor: 2.388